Patents by Inventor Walter Cabri

Walter Cabri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for purification of Carfilzomib
    Patent number: 10253066
    Abstract: The present invention relates to a process for the purification of Carfilzomib of Formula I that reduces the level of an acetamide impurity of Formula II preferably below 0.10 wt %.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: April 9, 2019
    Assignee: FRESENIUS KABI ONCOLOGY LIMITED
    Inventors: Maneesh Kumar Pandey, Raj Narayan Tiwari, Sarbjot Singh Sokhi, Govind Singh, Saswata Lahiri, Walter Cabri
  • PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES
    Publication number: 20180362588
    Abstract: The present invention provides a manufacturing process for preparing a peptide, preferably a decapeptide, such as degarelix, by incorporating p-nitro-phenylalanin in the amino acid sequence preferably during stepwise solid phase synthesis, and converting these into the required amino acids Aph(Hor) and/or D-Aph(Cbm), preferably while attached to a solid phase. The invention further provides intermediates useful in the manufacturing process.
    Type: Application
    Filed: December 19, 2016
    Publication date: December 20, 2018
    Inventors: Antonio RICCI, Jacopo ZANON, Walter CABRI, Ivan GURYANOV, Andrea ORLANDIN, Barbara BIONDI, Fernando FORMAGGIO, Dario VISENTINI
  • PROCESS FOR THE PREPARATION OF SUGAMMADEX AND ITS INTERMEDIATES
    Publication number: 20180355070
    Abstract: The present application provides an improved process for the preparation of sugammadex which comprises the halogenation of ?-cyclodextrin in a suitable organic solvent to give 6-per-deoxy-6-per-halo-?-cyclodextrin, wherein halo is bromo or chloro, reacting the halogenated ?-cyclodextrin with 3-mercaptopropionic acid in the presence of alkoxide base to obtain sugammadex of formula I. This application also provides isolation of 6-per-deoxy-6-per-chloro-?-cyclodextrin as a crystalline compound and its use for the preparation of sugammadex of formula (I).
    Type: Application
    Filed: November 23, 2016
    Publication date: December 13, 2018
    Applicant: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Walter CABRI, Antonio RICCI, Jacopo ZANON, Saswata LAHIRI, Govind SINGH, Dominik HECKMANN
  • CRYSTALLINE FORMS OF PER-CHLORO-GAMMA-CYCLODEXTRINES
    Publication number: 20180346608
    Abstract: The present application provides crystalline forms of 6-per-deoxy-6-per-chloro-?-cyclodextrin, and polymorphs thereof. The present application also provides methods for preparing said polymorphs by dissolving 6-per-deoxy-6-per-chloro-?-cyclodextrin in dimethylformamide and using an anti-solvent of a water/alcohol mixture.
    Type: Application
    Filed: November 24, 2016
    Publication date: December 6, 2018
    Applicant: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Walter CABRI, Antonio RICCI, Jacopo ZANON, Saswata LAHIRI, Govind SINGH, Shivaji Haribhau SHELKE, Shridhar REDDY, Nitin KUMAR, Madan SINGH
  • POLYMORPHIC FORMS OF AFATINIB FREE BASE AND AFATINIB DIMALEATE
    Publication number: 20180312494
    Abstract: The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.
    Type: Application
    Filed: June 10, 2016
    Publication date: November 1, 2018
    Applicant: FRESENIUS KABI ONCOLOGY LTD.
    Inventors: Walter CABRI, Saswata LAHIRI, Bhuwan Bhaskar MISHRA, Abul AZIM, Nilendu PANDA, Poli Reddy BHAVANAM, Krishanu RAY, Nikunj KACHHADIA, Kumber SINGH
  • A PROCESS FOR THE PREPARATION OF XYLENE LINKED CYCLAM COMPOUNDS
    Publication number: 20180244635
    Abstract: The present invention relates to an improved process for the preparation of xylene linked cyclam compounds. More particularly the invention provides a process for preparation of high purity plerixafor which does not involve the use of expensive chemicals, hazardous reagents or tedious purification techniques. Invention also provides novel intermediate useful for preparation of desired compound in high purity.
    Type: Application
    Filed: September 1, 2016
    Publication date: August 30, 2018
    Applicant: FRESENIUS KABI ONCOLOGY LTD.
    Inventors: Hemant Kumar SINGH, Sandeep KUMAR, Ghanashyam Madhukar SONAVANE, Vishal HANDA, Chandan Kumar GUPTA, Sunil SANGHANI, Potru SIVAIAH, Saswata LAHIRI, Walter CABRI, Nitin GUPTA
  • A PROCESS FOR PURIFICATION OF CARFILZOMIB
    Publication number: 20180002377
    Abstract: The present invention relates to a process for the purification of Carfiizomib of Formula I that reduces the level of an acetamide impurity of Formula II preferably below 0.10 wt %. Formula I Formula II.
    Type: Application
    Filed: December 1, 2015
    Publication date: January 4, 2018
    Inventors: Maneesh Kumar Pandey, Raj Narayan Tiwari, Sarbjot Singh Sokhi, Govind Singh, Saswata Lahiri, Walter Cabri
  • Amorphous form of a thiocolchicine derivative
    Patent number: 9688625
    Abstract: The present invention refers to an amorphous form of a thiocolchicine derivative, IDN 5404, to a process for producing it and to pharmaceutical compositions thereof. The amorphous form is characterized by the XRPD pattern, DSC profile and/or TG/DTA profile.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: June 27, 2017
    Assignee: INDENA S.P.A.
    Inventors: Walter Cabri, Federico Peterlongo, Daniele Ciceri, Andrea Gambini
  • Crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof
    Patent number: 9586919
    Abstract: The present invention relates to a new anhydrous crystalline form of Cabazitaxel of formula (I), designated as form H. A further object of the present invention is a processes for the preparation of the above mentioned form H by recrystallization of Cabazitaxel from a mixture of decanoyl- and octanoyl triglycerides or from glycerol trioctanoate. Form H of Cabazitaxel is useful for the preparation of Cabazitaxel, Cabazitaxel salts, and polymorphic forms thereof. It is also particularly useful as a medicament, especially for the treatment of cancers.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: March 7, 2017
    Assignee: INDENA S.P.A.
    Inventors: Walter Cabri, Daniele Ciceri, Luca Domenighini, Andrea Gambini, Federico Peterlongo
  • AMORPHOUS FORM OF A THIOCOLCHICINE DERIVATIVE
    Publication number: 20170022155
    Abstract: The present invention refers to an amorphous form of a thiocolchicine derivative, IDN 5404, to a process for producing it and to pharmaceutical compositions thereof. The amorphous form is characterised by the XRPD pattern, DSC profile and/or TG/DTA profile.
    Type: Application
    Filed: March 26, 2015
    Publication date: January 26, 2017
    Applicants: Indena S.P.A., Indena S.P.A.
    Inventors: Walter Cabri, Federico Peterlongo, Daniele Ciceri, Andrea Gambini
  • CRYSTALLINE SOLVATE FORMS OF CABAZITAXEL
    Publication number: 20160257663
    Abstract: The present invention relates to new crystalline forms of Cabazitaxel of formula (I). Specifically, the present invention provides four new crystalline solvate forms of Cabazitaxel, designated as form S2 (solvate with 2-methyltetrahydrofuran), form S4 (solvate with tent-butyl acetate), form S5 (solvate with dimethylcarbonate) and form S6 (solvate with N-methyl-2-pyrrolidinone). A further object of the present invention are processes for the preparation of the above mentioned crystalline forms. The crystalline solvate forms of the invention are especially useful for the preparation of Cabazitaxel, Cabazitaxel salts, and polymorphic forms thereof.
    Type: Application
    Filed: October 9, 2014
    Publication date: September 8, 2016
    Inventors: Walter CABRI, Daniele CICERI, Luca DOMENIGHINI, Andrea GAMBINI, Federico PETERLONGO
  • A CRYSTALLINE ANHYDROUS FORM OF CABAZITAXEL, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20160244420
    Abstract: The present invention relates to a new anhydrous crystalline form of Cabazitaxel of formula (I), designated as form H. A further object of the present invention is a processes for the preparation of the above mentioned form H by recrystallization of Cabazitaxel from a mixture of decanoyl- and octanoyl triglycerides or from glycerol trioctanoate. Form H of Cabazitaxel is useful for the preparation of Cabazitaxel, Cabazitaxel salts, and polymorphic forms thereof. It is also particularly useful as a medicament, especially for the treatment of cancers.
    Type: Application
    Filed: October 9, 2014
    Publication date: August 25, 2016
    Inventors: Walter Cabri, Daniele Ciceri, Luca Domenighini, Andrea Gambini, Federico Peterlongo
  • Aryl triazole compounds with antitumoural activity
    Patent number: 9302998
    Abstract: The present invention relates to aryl triazole derivatives of Formula I having antitumoural activity through, as one possible biological target, the molecular chaperone heat shock protein 90 (Hsp90) inhibition. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of Hsp90 is responsive, and the pharmaceutical composition containing such compounds.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: April 5, 2016
    Assignee: SIGMA-TAU RESEARCH SWITZERLAND S.A.
    Inventors: Giuseppe Giannini, Walter Cabri, Loredana Vesci, Maria Luisa Cervoni, Claudio Pisano, Maurizio Taddei, Serena Ferrini
  • OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS
    Publication number: 20160002244
    Abstract: The present invention relates to new triazolyl purine derivatives of formula (I), processes for their preparation, and to pharmaceutical compositions containing them for the treatment of neurological disorders or cerebral ischaemia for which inhibition of adenosine A2A receptor will result at improving the health state of a patient.
    Type: Application
    Filed: August 10, 2015
    Publication date: January 7, 2016
    Inventors: Walter CABRI, Patrizia MINETTI, Giovanni PIERSANTI, Giorgio TARZIA
  • Process for the synthesis of 7-chloro-4-(piperazin-1-yl)-quinoline
    Patent number: 9206133
    Abstract: The present invention provides a new process of synthesis of a polymorph of 7-chloro-4-(piperazin-1-yl)-quinoline of Formula I. Said quinoline compound is substantially pure of any impurities. The present invention further provides the use of the above-mentioned polymorph of 7-chloro-4-(piperazin-1-yl)-quinoline in the synthesis of piperaquine or one of its pharmaceutically acceptable salts.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: December 8, 2015
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Walter Cabri, Roberto Castagnani, Silvia Armaroli, Gianandrea Quattrociocchi, Vincenzo Colangeli
  • Crystalline (6R,7R)-7-{2-(5-amino-[1,2,4] thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1?-tert-butoxycarbonyl-2-oxo-[1,3?]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use
    Patent number: 9163034
    Abstract: A solid DMSO solvate of a compound of formula (I) is described, which is a useful intermediate for preparing the broad spectrum antibiotics Ceftobiprole and Ceftobiprole Medocaril.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: October 20, 2015
    Assignee: BASILEA PHARMACEUTICA AG
    Inventors: Marco Alpegiani, Jr., Walter Cabri, Markus Heubes, Davide Longoni, Michael Schleimer
  • Oxidated derivatives of triazolylpurines useful as ligands of the adenosine A2A receptor and their use as medicaments
    Patent number: 9133197
    Abstract: The present invention relates to new triazolyl purine derivatives of formula (I), processes for their preparation, and to pharmaceutical compositions containing them for the treatment of neurological disorders or cerebral ischaemia for which inhibition of adenosine A2A receptor will result at improving the health state of a patient.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: September 15, 2015
    Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Walter Cabri, Patrizia Minetti, Giovanni Piersanti, Giorgio Tarzia
  • Thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments
    Patent number: 8927533
    Abstract: The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC is responsive, and the pharmaceutical composition containing such compounds.
    Type: Grant
    Filed: September 17, 2012
    Date of Patent: January 6, 2015
    Assignee: SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Giuseppe Giannini, Walter Cabri, Gianfranco Battistuzzi, Davide Vignola, Nicola Fanto', Claudio Pisano, Loredana Vesci
  • CRYSTALLINE (6R,7R)-7--3- [(R)-1'-TERT-BUTOXYCARBONYL-2-OXO-[1,3']BIPYRROLIDINYL-(3E)-YLIDENEMETHYL]-8-OXO-5-THIA-1-AZA-BICYCLO[4.2.0] OCT-2-ENE-2-CARBOXYLIC ACID BENZHYDRYL ESTER; ITS MANUFACTURE AND USE
    Publication number: 20150005491
    Abstract: A solid DMSO solvate of a compound of formula (I) is described, which is a useful intermediate for preparing the broad spectrum antibiotics Ceftobiprole and Ceftobiprole Medocaril.
    Type: Application
    Filed: September 15, 2014
    Publication date: January 1, 2015
    Applicant: Basilea Pharmaceutica AG
    Inventors: Marco Alpegiani, JR., Walter Cabri, Markus Heubes, Davide Longoni, Michael Schleimer
  • ARYL TRIAZOLE COMPOUNDS WITH ANTITUMOURAL ACTIVITY
    Publication number: 20140329812
    Abstract: The present invention relates to aryl triazole derivatives of Formula I having antitumoural activity through, as one possible biological target, the molecular chaperone heat shock protein 90 (Hsp90) inhibition. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of Hsp90 is responsive, and the pharmaceutical composition containing such compounds.
    Type: Application
    Filed: December 13, 2011
    Publication date: November 6, 2014
    Applicant: SIGMA-TAU RESEARCH SWITZERLAND S.A.
    Inventors: Giuseppe Giannini, Walter Cabri, Loredana Vesci, Maria Luisa Cervoni, Claudio Pisano, Maurizio Taddei, Serena Ferrini